Company news

Cognition Therapeutics, Inc. news in 2026

Cognition Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update

November 5, 2026

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

November 2, 2026

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

October 22, 2026

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045

October 13, 2026

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

September 29, 2026

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

September 8, 2026

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

August 6, 2026

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

July 13, 2026

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

June 24, 2026

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

June 16, 2026

Cognition Therapeutics Participating in Upcoming Investor Conferences

June 1, 2026

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

May 21, 2026

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 14, 2026

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

May 7, 2026

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

April 6, 2026

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

March 25, 2026

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

March 22, 2026

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

March 17, 2026

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

March 2, 2026

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

February 5, 2026

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

January 27, 2026

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

January 6, 2026

Calls in 2026

Decks in 2026